A Randomized, Placebo-controlled, Parallel-group, Investigator- and Participant-blinded Phase 2a Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
Latest Information Update: 09 Jan 2025
At a glance
- Drugs DFV 890 (Primary)
- Indications Myocardial infarction
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 07 Jan 2025 Status changed from recruiting to completed.
- 03 Oct 2024 Planned End Date changed from 14 Mar 2025 to 25 Dec 2024.
- 03 Oct 2024 Planned primary completion date changed from 6 Mar 2025 to 17 Dec 2024.